A timely critique of AI drug discovery hype. The real test is whether these technologies can consistently translate computational breakthroughs into validated, clinically meaningful outcomes.
A thought-provoking piece—and an important reality check for the AI drug-discovery industry.
1. Benchmarks are not medicines. Strong AI performance demonstrates computational capability; the real test is whether it increases the probability of a safe, effective drug reaching patients.
2. Biology remains the bottleneck. Structure prediction, generative chemistry and omics are powerful—but cannot replace causal biology, experimental validation and clinical evidence.
3. End-to-end systems matter. Drug discovery involves thousands of interconnected decisions across discovery, DMPK, toxicology, CMC and clinical development—not one impressive AI model.
4. AI needs biological guardrails. Predictions must be challenged through wet-lab validation, translational models, biomarkers and human data. The physical world does not run at GPU speed.
5. Value must ultimately be measured differently. The real KPI should be validated medicines, clinical benefit and improved human health—not model performance, funding or valuation.
The industry is now entering an important phase where clinical evidence will separate AI promise from genuine therapeutic impact.
What do you think should be the most important KPI for AI drug discovery: predictive accuracy, development speed, clinical success, or patient outcomes?
I really like)) the Disclaimer: This article is written with the help of generative tools so beware of hallucinations. The images were generated using NanoBanana. Don’t buy, sell any securities, or take any drugs based on this article or any of its contents.
A timely critique of AI drug discovery hype. The real test is whether these technologies can consistently translate computational breakthroughs into validated, clinically meaningful outcomes.
A thought-provoking piece—and an important reality check for the AI drug-discovery industry.
1. Benchmarks are not medicines. Strong AI performance demonstrates computational capability; the real test is whether it increases the probability of a safe, effective drug reaching patients.
2. Biology remains the bottleneck. Structure prediction, generative chemistry and omics are powerful—but cannot replace causal biology, experimental validation and clinical evidence.
3. End-to-end systems matter. Drug discovery involves thousands of interconnected decisions across discovery, DMPK, toxicology, CMC and clinical development—not one impressive AI model.
4. AI needs biological guardrails. Predictions must be challenged through wet-lab validation, translational models, biomarkers and human data. The physical world does not run at GPU speed.
5. Value must ultimately be measured differently. The real KPI should be validated medicines, clinical benefit and improved human health—not model performance, funding or valuation.
The industry is now entering an important phase where clinical evidence will separate AI promise from genuine therapeutic impact.
What do you think should be the most important KPI for AI drug discovery: predictive accuracy, development speed, clinical success, or patient outcomes?
I really like)) the Disclaimer: This article is written with the help of generative tools so beware of hallucinations. The images were generated using NanoBanana. Don’t buy, sell any securities, or take any drugs based on this article or any of its contents.
It is true, I did use some of the tools
Thank you for the reality check. Let’s see what makes it past phase III trials